» Articles » PMID: 38009693

Effect of Previous Heterologous Flavivirus Vaccinations on Human Antibody Responses in Tick-borne Encephalitis and Dengue Virus Infections

Overview
Journal J Med Virol
Specialty Microbiology
Date 2023 Nov 27
PMID 38009693
Authors
Affiliations
Soon will be listed here.
Abstract

Arthropod-borne flaviviruses include a number of medically relevant human pathogens such as the mosquito-borne dengue (DEN), Zika, and yellow fever (YF) viruses as well as tick-borne encephalitis virus (TBEV). All flaviviruses are antigenically related and anamnestic responses due to prior immunity can modulate antibody specificities in subsequent infections or vaccinations. In our study, we analyzed the induction of broadly flavivirus cross-reactive antibodies in tick-borne encephalitis (TBE) and DEN patients without or with prior flavivirus exposure through TBE and/or YF vaccination, and determined the contribution of these antibodies to TBE and dengue virus (DENV) neutralization. In addition, we investigated the formation of cross-reactive antibodies in TBE-vaccination breakthroughs (VBTs). A TBEV infection without prior YF or TBE vaccination induced predominantly type-specific antibodies. In contrast, high levels of broadly cross-reactive antibodies were found in samples from TBE patients prevaccinated against YF as well as in DEN patients prevaccinated against TBE and/or YF. While these cross-reactive antibodies did not neutralize TBEV, they were effective in neutralizing DENV. This discrepancy points to structural differences between the two viruses and indicates that broadly cross-reactive epitopes are less accessible in TBEV than in DENV. In TBE VBT infections, type-specific antibodies dominated the antibody response, thus revealing no difference from that of unvaccinated TBE patients. Our results emphasize significant differences in the structural properties of different flaviviruses that have an impact on the induction of broadly cross-reactive antibodies and their functional activities in virus neutralization.

Citing Articles

Antigen-specific T cell responses following single and co-administration of tick-borne encephalitis, Japanese encephalitis, and yellow fever virus vaccines: Results from an open-label, non-randomized clinical trial-cohort.

Wullimann D, Sandberg J, Akber M, Lofling M, Gredmark-Russ S, Michaelsson J PLoS Negl Trop Dis. 2025; 19(2):e0012693.

PMID: 40019865 PMC: 11893121. DOI: 10.1371/journal.pntd.0012693.


Effect of previous heterologous flavivirus vaccinations on human antibody responses in tick-borne encephalitis and dengue virus infections.

Rossbacher L, Malafa S, Huber K, Thaler M, Aberle S, Aberle J J Med Virol. 2023; 95(11):e29245.

PMID: 38009693 PMC: 10952712. DOI: 10.1002/jmv.29245.

References
1.
Lin H, Tsai W, Liu I, Li P, Liao M, Tsai J . Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis. 2012; 6(1):e1447. PMC: 3250511. DOI: 10.1371/journal.pntd.0001447. View

2.
de Silva A, Harris E . Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. Cold Spring Harb Perspect Biol. 2017; 10(6). PMC: 5983190. DOI: 10.1101/cshperspect.a029371. View

3.
Chaichana P, Okabayashi T, Puiprom O, Sasayama M, Sasaki T, Yamashita A . Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients. PLoS One. 2014; 9(3):e92173. PMC: 3958444. DOI: 10.1371/journal.pone.0092173. View

4.
Mukherjee S, Sirohi D, Dowd K, Chen Z, Diamond M, Kuhn R . Enhancing dengue virus maturation using a stable furin over-expressing cell line. Virology. 2016; 497:33-40. PMC: 5502530. DOI: 10.1016/j.virol.2016.06.022. View

5.
Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H . Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002; 40(7):2323-30. PMC: 120575. DOI: 10.1128/JCM.40.7.2323-2330.2002. View